News

Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA. “Dosing the first patient in our clinical study of ADI-001 in treatment-refractory RA marks an important milestone in our Phase 1 program, which is now en.

10/16/2025

Adicet Bio, Inc. - Special Call

Adicet Bio, Inc. - Special Call Company Participants Chen Schor - CEO, President & Director Julie Maltzman - Chief Medical Officer Blake Aftab - Senior VP & Chief Scientific Officer Conference Call Participants Jenna Li - Jefferies LLC, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Karina Rabayeva - Truist Securities, Inc., Research Division John Newman - Canaccord Genuity Corp., Research Division Robert Driscoll - Wedbush Securities Inc., Research Division Reni Benjamin - Citizens JMP Securities, LLC, Research Division Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Robert Burns - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, everyone, and welcome to the Adicet webcast.

10/07/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Adicet Bio, Inc. (ACET) a buy, sell, or hold?

Adicet Bio, Inc. (ACET) can sell. Click on Rating Page for detail.

What is Adicet Bio, Inc.'s stock price?

The price of Adicet Bio, Inc. (ACET) is 0.7505 and it was updated on 2025-10-30 01:01:35.

Is Adicet Bio, Inc. (ACET) overvalued or undervalued?

Currently Adicet Bio, Inc. (ACET) is in undervalued.

News

From:

To:

News
Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2 Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in autoimmune diseases showed encouraging signs. Tue, Oct. 07, 2025
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 10,000,000 shares of common stock. The shares of common stock are b. Tue, Oct. 07, 2025
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced initial safety and efficacy data from the first seven patients dosed with ADI-001 in the ongoing Phase 1 study evaluating ADI-001 as a potential treatment for patients with autoimmune diseases. The data cut as of August 31, 2025, includes seven patients (five. Tue, Oct. 07, 2025
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on September 30, 2025. One individual was hired by Adicet in September 2025 and granted new hire non-qualified stock options to purchase 9,800 shares of Adicet's common stock with an exercise price of $0.81 per share, the closing. Tue, Sep. 30, 2025
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Tue, Sep. 30, 2025

SEC Filings

SEC Filings
Adicet Bio, Inc. (ACET) - SCHEDULE 13D/A SEC Filings 10/10/2025
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/10/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/07/2025
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 10/07/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 08/07/2025
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 08/07/2025
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 07/25/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/23/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/13/2025
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/13/2025
Adicet Bio, Inc. (ACET) - SCHEDULE 13G/A SEC Filings 05/15/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/06/2025
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 05/06/2025
Adicet Bio, Inc. (ACET) - DEFA14A SEC Filings 04/29/2025
Adicet Bio, Inc. (ACET) - DEF 14A SEC Filings 04/29/2025
Adicet Bio, Inc. (ACET) - ARS SEC Filings 04/29/2025
Adicet Bio, Inc. (ACET) - 4 SEC Filings 04/21/2025
Adicet Bio, Inc. (ACET) - 3 SEC Filings 04/21/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 04/17/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 04/11/2025
Adicet Bio, Inc. (ACET) - S-8 POS SEC Filings 03/26/2025
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 03/18/2025
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 03/17/2025
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 03/06/2025
Adicet Bio, Inc. (ACET) - S-3 SEC Filings 03/06/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/06/2025
Adicet Bio, Inc. (ACET) - 10-K - Current report SEC Filings 03/06/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 02/05/2025
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/04/2025
Adicet Bio, Inc. (ACET) - 4 SEC Filings 01/28/2025
Adicet Bio, Inc. (ACET) - 3 SEC Filings 01/23/2025
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 12/19/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/27/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/18/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/15/2024
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 11/14/2024
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 11/13/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/06/2024
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 11/06/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/16/2024
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 10/08/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 09/30/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 09/19/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 09/10/2024
Adicet Bio, Inc. (ACET) - 4 SEC Filings 08/23/2024
Adicet Bio, Inc. (ACET) - 4 SEC Filings 08/20/2024
Adicet Bio, Inc. (ACET) - 3 SEC Filings 08/20/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 08/19/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 08/13/2024
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 08/13/2024
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 07/10/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/08/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/24/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/07/2024
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/07/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/05/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/14/2024
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 05/14/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/10/2024
Adicet Bio, Inc. (ACET) - DEFR14A SEC Filings 04/26/2024
Adicet Bio, Inc. (ACET) - ARS SEC Filings 04/24/2024
Adicet Bio, Inc. (ACET) - DEFA14A SEC Filings 04/23/2024
Adicet Bio, Inc. (ACET) - DEF 14A SEC Filings 04/23/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 04/22/2024
Adicet Bio, Inc. (ACET) - PRE 14A SEC Filings 04/12/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/22/2024
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 03/22/2024
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 03/21/2024
Adicet Bio, Inc. (ACET) - S-8 POS SEC Filings 03/19/2024
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 03/19/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/19/2024
Adicet Bio, Inc. (ACET) - 10-K - Current report SEC Filings 03/19/2024
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 02/27/2024
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/14/2024
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 02/12/2024
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/07/2024
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 02/07/2024
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 02/05/2024
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/02/2024
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 01/31/2024
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 01/29/2024
Adicet Bio, Inc. (ACET) - 4 SEC Filings 01/26/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 01/24/2024
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 01/24/2024
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 01/23/2024
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 01/22/2024
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 01/19/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 01/16/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 01/04/2024
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/13/2023
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/08/2023
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 11/08/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/16/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/03/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/02/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 08/16/2023
Adicet Bio, Inc. (ACET) - S-8 POS SEC Filings 08/09/2023
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 08/09/2023
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 08/09/2023
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 08/09/2023
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/11/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 07/11/2023
Adicet Bio, Inc. (ACET) - 3 SEC Filings 07/11/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/30/2023
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 06/29/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/29/2023
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/26/2023
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/05/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/02/2023
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/18/2023
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/09/2023
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 05/09/2023
Adicet Bio, Inc. (ACET) - DEFA14A SEC Filings 04/18/2023
Adicet Bio, Inc. (ACET) - DEF 14A SEC Filings 04/18/2023
Adicet Bio, Inc. (ACET) - ARS SEC Filings 04/18/2023
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 03/15/2023
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/15/2023
Adicet Bio, Inc. (ACET) - 10-K - Current report SEC Filings 03/15/2023
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 03/13/2023
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/10/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/17/2023
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/14/2023
Adicet Bio, Inc. (ACET) - 5 SEC Filings 02/14/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/14/2023
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 02/13/2023
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 02/03/2023
Adicet Bio, Inc. (ACET) - 4 SEC Filings 01/26/2023
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 01/11/2023
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 12/23/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 12/12/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 12/08/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 11/15/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/10/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 11/09/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/08/2022
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 11/08/2022
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 11/08/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 11/04/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/03/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/21/2022
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 10/17/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/14/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/05/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/04/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 09/16/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 09/13/2022
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 08/11/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 08/10/2022
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 08/10/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 08/08/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 08/05/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 08/03/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 07/07/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/21/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/06/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/03/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/03/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/26/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/12/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 05/12/2022
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 05/12/2022
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 05/10/2022
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 05/10/2022
Adicet Bio, Inc. (ACET) - CORRESP SEC Filings 05/05/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/05/2022
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 04/22/2022
Adicet Bio, Inc. (ACET) - DEFA14A SEC Filings 04/21/2022
Adicet Bio, Inc. (ACET) - DEF 14A SEC Filings 04/21/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 04/19/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 04/05/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/24/2022
Adicet Bio, Inc. (ACET) - UPLOAD SEC Filings 03/16/2022
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 03/16/2022
Adicet Bio, Inc. (ACET) - S-3/A SEC Filings 03/16/2022
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 03/15/2022
Adicet Bio, Inc. (ACET) - S-3 SEC Filings 03/15/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/15/2022
Adicet Bio, Inc. (ACET) - 10-K - Current report SEC Filings 03/15/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 03/11/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/17/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/16/2022
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/14/2022
Adicet Bio, Inc. (ACET) - 5 SEC Filings 02/14/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/14/2022
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 02/03/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/01/2022
Adicet Bio, Inc. (ACET) - 4 SEC Filings 01/11/2022
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 12/15/2021
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 12/14/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 12/14/2021
Adicet Bio, Inc. (ACET) - 4/A SEC Filings 12/13/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 12/10/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 12/10/2021
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 12/09/2021
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 12/07/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 12/06/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/18/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 11/18/2021
Adicet Bio, Inc. (ACET) - 3 SEC Filings 11/18/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/12/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/10/2021
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 11/10/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/29/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/25/2021
Adicet Bio, Inc. (ACET) - 3/A SEC Filings 10/14/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/13/2021
Adicet Bio, Inc. (ACET) - 3 SEC Filings 10/13/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/05/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 09/13/2021
Adicet Bio, Inc. (ACET) - 10-K/A - Current report SEC Filings 08/16/2021
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 08/12/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 08/12/2021
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 08/12/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/30/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/26/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/23/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/01/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/21/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/17/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/14/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/08/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/07/2021
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 05/24/2021
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 05/21/2021
Adicet Bio, Inc. (ACET) - 424B3 SEC Filings 05/21/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 05/21/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 05/20/2021
Adicet Bio, Inc. (ACET) - CORRESP SEC Filings 05/19/2021
Adicet Bio, Inc. (ACET) - UPLOAD SEC Filings 05/18/2021
Adicet Bio, Inc. (ACET) - 8-K/A - Current report SEC Filings 05/17/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/17/2021
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 05/17/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 05/14/2021
Adicet Bio, Inc. (ACET) - S-3 SEC Filings 05/13/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 05/07/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 05/04/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 04/29/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 04/22/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 04/09/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 04/08/2021
Adicet Bio, Inc. (ACET) - 4/A SEC Filings 04/01/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 04/01/2021
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 03/31/2021
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 03/31/2021
Adicet Bio, Inc. (ACET) - CORRESP SEC Filings 03/26/2021
Adicet Bio, Inc. (ACET) - UPLOAD SEC Filings 03/18/2021
Adicet Bio, Inc. (ACET) - DEFA14A SEC Filings 03/18/2021
Adicet Bio, Inc. (ACET) - DEF 14A SEC Filings 03/18/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 03/18/2021
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 03/16/2021
Adicet Bio, Inc. (ACET) - 4/A SEC Filings 03/16/2021
Adicet Bio, Inc. (ACET) - 3/A SEC Filings 03/16/2021
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 03/12/2021
Adicet Bio, Inc. (ACET) - S-3 SEC Filings 03/12/2021
Adicet Bio, Inc. (ACET) - 10-K - Current report SEC Filings 03/12/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/11/2021
Adicet Bio, Inc. (ACET) - 10-K - Current report SEC Filings 03/11/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/10/2021
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 03/08/2021
Adicet Bio, Inc. (ACET) - SC 13D SEC Filings 03/08/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/04/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 03/04/2021
Adicet Bio, Inc. (ACET) - 3 SEC Filings 03/04/2021
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/23/2021
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 02/19/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 02/19/2021
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 02/18/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/18/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/17/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 02/16/2021
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 02/12/2021
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 02/11/2021
Adicet Bio, Inc. (ACET) - S-3MEF SEC Filings 02/10/2021
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 02/10/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 02/09/2021
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 02/09/2021
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/01/2021
Adicet Bio, Inc. (ACET) - S-8 POS SEC Filings 01/28/2021
Adicet Bio, Inc. (ACET) - 4 SEC Filings 01/15/2021
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 01/05/2021
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 12/03/2020
Adicet Bio, Inc. (ACET) - 4 SEC Filings 12/03/2020
Adicet Bio, Inc. (ACET) - 3 SEC Filings 12/03/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 12/01/2020
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 12/01/2020
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 11/12/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/05/2020
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 11/05/2020
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/29/2020
Adicet Bio, Inc. (ACET) - 3 SEC Filings 10/29/2020
Adicet Bio, Inc. (ACET) - 4 SEC Filings 10/27/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/26/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/22/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/08/2020
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 10/02/2020
Adicet Bio, Inc. (ACET) - 8-K/A - Current report SEC Filings 10/01/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 09/30/2020
Adicet Bio, Inc. (ACET) - SC 13D SEC Filings 09/24/2020
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 09/22/2020
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 09/21/2020
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 09/18/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 09/18/2020
Adicet Bio, Inc. (ACET) - 3 SEC Filings 09/18/2020
Adicet Bio, Inc. (ACET) - 4 SEC Filings 09/17/2020
Adicet Bio, Inc. (ACET) - 3 SEC Filings 09/17/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 09/16/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 09/15/2020
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 08/21/2020
Adicet Bio, Inc. (ACET) - 424B3 SEC Filings 08/21/2020
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 08/20/2020
Adicet Bio, Inc. (ACET) - S-4/A SEC Filings 08/19/2020
Adicet Bio, Inc. (ACET) - CORRESP SEC Filings 08/19/2020
Adicet Bio, Inc. (ACET) - S-4/A SEC Filings 08/12/2020
Adicet Bio, Inc. (ACET) - CORRESP SEC Filings 08/12/2020
Adicet Bio, Inc. (ACET) - UPLOAD SEC Filings 08/06/2020
Adicet Bio, Inc. (ACET) - 425 SEC Filings 08/05/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/30/2020
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 07/30/2020
Adicet Bio, Inc. (ACET) - S-4/A SEC Filings 07/29/2020
Adicet Bio, Inc. (ACET) - CORRESP SEC Filings 07/29/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/28/2020
Adicet Bio, Inc. (ACET) - 425 SEC Filings 07/28/2020
Adicet Bio, Inc. (ACET) - UPLOAD SEC Filings 07/21/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/07/2020
Adicet Bio, Inc. (ACET) - S-4 SEC Filings 06/23/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/23/2020
Adicet Bio, Inc. (ACET) - 425 SEC Filings 06/23/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/05/2020
Adicet Bio, Inc. (ACET) - 4 SEC Filings 06/05/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 06/02/2020
Adicet Bio, Inc. (ACET) - 425 SEC Filings 06/02/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/28/2020
Adicet Bio, Inc. (ACET) - SC 13D SEC Filings 05/08/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/07/2020
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 05/07/2020
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 05/05/2020
Adicet Bio, Inc. (ACET) - DEFA14A SEC Filings 04/30/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 04/30/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 04/29/2020
Adicet Bio, Inc. (ACET) - 425 SEC Filings 04/29/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 04/03/2020
Adicet Bio, Inc. (ACET) - DEFA14A SEC Filings 03/27/2020
Adicet Bio, Inc. (ACET) - DEF 14A SEC Filings 03/27/2020
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 03/12/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/12/2020
Adicet Bio, Inc. (ACET) - 10-K - Current report SEC Filings 03/12/2020
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 02/19/2020
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/14/2020
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/13/2020
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/07/2020
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 02/06/2020
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 12/30/2019
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 12/19/2019
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 12/19/2019
Adicet Bio, Inc. (ACET) - 4 SEC Filings 12/19/2019
Adicet Bio, Inc. (ACET) - 4 SEC Filings 12/17/2019
Adicet Bio, Inc. (ACET) - 4 SEC Filings 12/12/2019
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 12/10/2019
Adicet Bio, Inc. (ACET) - 4 SEC Filings 12/06/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 12/03/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 12/02/2019
Adicet Bio, Inc. (ACET) - 4 SEC Filings 11/19/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/18/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/15/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/05/2019
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 11/05/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/03/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 08/14/2019
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 08/14/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/23/2019
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 06/10/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/15/2019
Adicet Bio, Inc. (ACET) - 4 SEC Filings 05/15/2019
Adicet Bio, Inc. (ACET) - 3 SEC Filings 05/15/2019
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 05/15/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/10/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/09/2019
Adicet Bio, Inc. (ACET) - 4 SEC Filings 05/09/2019
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 04/10/2019
Adicet Bio, Inc. (ACET) - DEFA14A SEC Filings 03/27/2019
Adicet Bio, Inc. (ACET) - DEF 14A SEC Filings 03/27/2019
Adicet Bio, Inc. (ACET) - SC 13D/A SEC Filings 03/25/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/21/2019
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 03/20/2019
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 03/18/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/18/2019
Adicet Bio, Inc. (ACET) - 424B5 SEC Filings 03/18/2019
Adicet Bio, Inc. (ACET) - 10-K - Current report SEC Filings 03/18/2019
Adicet Bio, Inc. (ACET) - 4 SEC Filings 02/28/2019
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 02/13/2019
Adicet Bio, Inc. (ACET) - UPLOAD SEC Filings 02/11/2019
Adicet Bio, Inc. (ACET) - CORRESP SEC Filings 02/08/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 02/07/2019
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 02/01/2019
Adicet Bio, Inc. (ACET) - S-3 SEC Filings 02/01/2019
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 01/28/2019
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 01/07/2019
Adicet Bio, Inc. (ACET) - 4 SEC Filings 12/17/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/13/2018
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 11/13/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 11/06/2018
Adicet Bio, Inc. (ACET) - 4 SEC Filings 11/06/2018
Adicet Bio, Inc. (ACET) - 3 SEC Filings 11/06/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 10/16/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 09/18/2018
Adicet Bio, Inc. (ACET) - 4 SEC Filings 09/18/2018
Adicet Bio, Inc. (ACET) - 3 SEC Filings 09/18/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 08/15/2018
Adicet Bio, Inc. (ACET) - 4 SEC Filings 08/15/2018
Adicet Bio, Inc. (ACET) - 3 SEC Filings 08/15/2018
Adicet Bio, Inc. (ACET) - SC 13G/A SEC Filings 08/10/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 08/09/2018
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 08/09/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/30/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 07/25/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/10/2018
Adicet Bio, Inc. (ACET) - 10-Q - Quarterly Report SEC Filings 05/10/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 05/09/2018
Adicet Bio, Inc. (ACET) - 10-K/A - Current report SEC Filings 04/27/2018
Adicet Bio, Inc. (ACET) - 4 SEC Filings 04/17/2018
Adicet Bio, Inc. (ACET) - 4 SEC Filings 04/12/2018
Adicet Bio, Inc. (ACET) - 4 SEC Filings 04/11/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/29/2018
Adicet Bio, Inc. (ACET) - 10-K - Current report SEC Filings 03/29/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 03/19/2018
Adicet Bio, Inc. (ACET) - 4 SEC Filings 03/14/2018
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 03/12/2018
Adicet Bio, Inc. (ACET) - SC 13G SEC Filings 02/14/2018
Adicet Bio, Inc. (ACET) - SC 13D SEC Filings 02/09/2018
Adicet Bio, Inc. (ACET) - SC 13D SEC Filings 02/02/2018
Adicet Bio, Inc. (ACET) - 8-K - Current report SEC Filings 01/30/2018
Adicet Bio, Inc. (ACET) - 4 SEC Filings 01/30/2018
Adicet Bio, Inc. (ACET) - S-8 SEC Filings 01/29/2018
Adicet Bio, Inc. (ACET) - 424B4 SEC Filings 01/29/2018
Adicet Bio, Inc. (ACET) - EFFECT SEC Filings 01/26/2018
Adicet Bio, Inc. (ACET) - CT ORDER SEC Filings 01/25/2018
Adicet Bio, Inc. (ACET) - CERT SEC Filings 01/25/2018
Adicet Bio, Inc. (ACET) - 3 SEC Filings 01/25/2018
Adicet Bio, Inc. (ACET) - CORRESP SEC Filings 01/23/2018
Adicet Bio, Inc. (ACET) - 8-A12B SEC Filings 01/22/2018
Adicet Bio, Inc. (ACET) - S-1/A SEC Filings 01/16/2018
Adicet Bio, Inc. (ACET) - CORRESP SEC Filings 01/05/2018
Adicet Bio, Inc. (ACET) - S-1 SEC Filings 12/29/2017
Adicet Bio, Inc. (ACET) - DRSLTR SEC Filings 12/22/2017
Adicet Bio, Inc. (ACET) - DRS/A SEC Filings 12/22/2017
Adicet Bio, Inc. (ACET) - UPLOAD SEC Filings 12/18/2017
Adicet Bio, Inc. (ACET) - DRSLTR SEC Filings 12/01/2017
Adicet Bio, Inc. (ACET) - DRS/A SEC Filings 12/01/2017
Adicet Bio, Inc. (ACET) - UPLOAD SEC Filings 11/22/2017
Adicet Bio, Inc. (ACET) - DRS SEC Filings 10/27/2017

Press Releases

StockPrice Release
Adicet bio announces first patient dosed in phase 1 clinical trial of adi-001 in treatment-refractory rheumatoid arthritis (ra) 10/16/2025
Adicet bio, inc. announces $80 million registered direct offering 10/07/2025
Adicet bio announces positive preliminary data from adi-001 phase 1 study in patients with lupus nephritis (ln) and systemic lupus erythematosus (sle) 10/07/2025
Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4) 09/30/2025
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 08/29/2025
Adicet bio to participate in a fireside chat at the 45th annual canaccord genuity growth conference 08/05/2025
Adicet bio announces first systemic sclerosis (ssc) patient dosed in ongoing phase 1 clinical trial of adi-001 in autoimmune diseases 07/24/2025
Adicet bio to participate in a fireside chat at the 2025 jefferies global healthcare conference 05/21/2025
Adicet bio reports first quarter 2025 financial results and provides business updates 05/06/2025
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 04/30/2025
Adicet bio announces oral presentation highlighting preclinical adi-270 data at the american society of gene and cell therapy (asgct) 28th annual meeting 04/28/2025
Adicet bio appoints michael grissinger to the board of directors 04/17/2025
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 03/31/2025
Adicet bio to participate in 2025 canaccord genuity horizons in oncology virtual conference 03/31/2025
Adicet bio reports fourth quarter and full year 2024 financial results and highlights recent company progress 03/06/2025
Adicet announces poster presentations highlighting adi-270 data at the society for immunotherapy of cancer (sitc) 2025 spring scientific meeting 03/03/2025
Adicet bio receives fda fast track designation for adi-001 for the treatment of refractory systemic lupus erythematosus (sle) with extrarenal involvement 02/05/2025
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 01/31/2025
Adicet bio to participate in a fireside chat at the guggenheim securities smid cap biotech conference 01/29/2025
Adicet bio provides corporate update and highlights expected 2025 milestones 01/08/2025
Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4) 12/31/2024
Adicet bio announces first patient dosed in the phase 1 clinical trial of adi-270 in metastatic/advanced clear cell renal cell carcinoma 12/19/2024
Adicet bio appoints julie maltzman, m.d. as chief medical officer 12/18/2024
Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4) 11/29/2024
Adicet opens enrollment for adi-270 phase 1 clinical trial in metastatic/advanced clear cell renal cell carcinoma 11/18/2024
Adicet bio presents clinical biomarker data for off-the-shelf car t cell therapy in an oral session at the american college of rheumatology (acr) convergence 2024 11/16/2024
Adicet bio to participate in upcoming investor conferences 11/01/2024
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 10/31/2024
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 09/30/2024
Adicet bio to present at the american society of gene & cell therapy's (asgct) 2024 advancing gene + cell therapies for cancer conference 09/30/2024
Adicet opens enrollment for adi-001 phase 1 clinical trial in autoimmune diseases 09/30/2024
Adi-001 clinical biomarker data demonstrate robust tissue trafficking and complete b cell depletion in secondary lymphoid tissue 09/19/2024
Ul solutions warns of potentially hazardous communications cable 08/30/2024
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 08/30/2024
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 07/31/2024
Adicet bio announces fda clearance of ind application for adi-270 in renal cell carcinoma 06/24/2024
Adicet bio receives fda fast track designation for adi-001 in lupus nephritis 06/05/2024
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 05/31/2024
Adicet bio to participate in a fireside chat at the 2024 jefferies healthcare conference 05/29/2024
Adicet reports first quarter 2024 financial results and provides business updates 05/14/2024
Adicet bio announces poster presentation of adi-270 preclinical data at the 2024 european hematology association (eha) hybrid congress 05/14/2024
Adicet bio to participate in a fireside chat at the citizens jmp life sciences conference 05/07/2024
Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4) 04/30/2024
Adicet bio highlights preclinical data supporting ind readiness for adi-270 in an oral presentation at the american society of gene and cell therapy (asgct) 27th annual meeting 04/22/2024
Adicet bio to participate in 2024 canaccord genuity horizons in oncology virtual conference 04/08/2024
Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4) 03/28/2024
Adicet reports fourth quarter and full year 2023 financial results and highlights recent company progress 03/19/2024
Adicet bio to participate in a fireside chat at the h.c. wainwright 2nd annual cell therapy virtual conference 03/11/2024
Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4) 02/29/2024
Adicet bio to participate in a fireside chat at the guggenheim healthcare talks 6th annual biotechnology conference 02/05/2024
Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4) 01/31/2024
Adicet bio, inc. announces closing of $98 million public follow-on offering and exercise in full of the underwriters' option to purchase additional shares 01/25/2024
Adicet bio, inc. announces pricing of public offering 01/22/2024
Adicet bio, inc. announces proposed public offering 01/22/2024
Adicet provides corporate update and highlights strategic priorities for 2024 01/04/2024
Adicet bio to host conference call to provide updates on its clinical pipeline and corporate outlook 01/03/2024
Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4) 12/29/2023
Adicet bio highlights adi-001 expansion, persistence and pharmacodynamic profile from ongoing phase 1 study at the 65th american society of hematology (ash) annual meeting 12/10/2023
Shareholder alert: purcell & lefkowitz llp announces shareholder investigation of adicet bio, inc. (nasdaq: acet) 12/04/2023
Adicet reports third quarter 2023 financial results and provides business updates 11/08/2023
Adicet bio to present at the 2023 jefferies london healthcare conference 11/07/2023
Adicet bio reports inducement grant under nasdaq listing rule 5635(c)(4) 10/31/2023
Adicet bio announces poster presentation at the upcoming 2023 molecular targets and cancer therapeutics conference 10/04/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 09/29/2023
Adicet bio to present three scientific posters highlighting its allogeneic gamma delta t cell platform and programs at the society for immunotherapy of cancer (sitc) 38th annual meeting 09/27/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 08/31/2023
Adicet reports second quarter 2023 financial results and provides business updates 08/09/2023
Adicet bio to participate in a fireside chat at the canaccord genuity 43rd annual growth conference 08/02/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 07/31/2023
Adicet announces appointment of katie peng to the board of directors 07/11/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 06/30/2023
Adicet bio reports positive data from ongoing adi-001 phase 1 trial in patients with relapsed or refractory aggressive b-cell non-hodgkin's lymphoma (nhl) 06/26/2023
Adicet bio to participate in a fireside chat at the 2023 jefferies healthcare conference 06/01/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 05/31/2023
Adicet bio presents positive preclinical data on adi-270 at the american society of gene and cell therapy (asgct) 26th annual meeting 05/18/2023
Adicet bio to present at the 2023 jmp securities life sciences conference 05/09/2023
Adicet reports first quarter 2023 financial results and provides business updates 05/09/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 04/28/2023
Adicet bio to participate in 2023 canaccord genuity horizons in oncology virtual conference 04/13/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 03/31/2023
Adicet reports fourth quarter and full year 2022 financial results and highlights recent company progress 03/15/2023
Adicet bio to participate in 2023 jefferies biotech on the bay summit 03/09/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 02/28/2023
Adicet bio to participate in a fireside chat at the 2023 guggenheim oncology conference 02/01/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 01/31/2023
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 12/30/2022
Adicet bio reports positive data from ongoing adi-001 phase 1 trial in patients with relapsed or refractory aggressive b-cell non-hodgkin's lymphoma (nhl) 12/10/2022
Adicet bio reports positive data from ongoing adi-001 phase 1 trial in patients with relapsed or refractory aggressive b-cell non-hodgkin’s lymphoma (nhl) 12/10/2022
Adicet bio to host investor webcast to discuss updated clinical data from ongoing adi-001 phase 1 trial in patients with relapsed or refractory aggressive b-cell non-hodgkin's lymphoma (nhl) 12/02/2022
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 11/30/2022
Adicet bio to present at the virtual jmp securities hematology and oncology summit 11/30/2022
Adicet bio appoints nancy boman, m.d., ph.d., as senior vice president and chief regulatory officer 11/29/2022
Adicet bio reports ash abstract data from ongoing adi-001 phase 1 trial in relapsed or refractory aggressive b-cell non-hodgkin's lymphoma (nhl) 11/03/2022
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 10/31/2022
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 09/30/2022
Adicet bio to present at upcoming investor conferences 09/07/2022
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 08/31/2022
Adicet reports second quarter 2022 financial results and provides business updates 08/10/2022
Adicet bio to present at upcoming investor conferences 08/01/2022
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 07/29/2022
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 07/01/2022
Adicet bio to present at upcoming investor conferences 06/21/2022
Adicet bio reports emerging data from adi-001 phase 1 trial at the american society of clinical oncology annual meeting 06/06/2022
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 06/03/2022
Adicet bio reports positive clinical update from adi-001 phase 1 trial in relapsed/refractory non-hodgkin's lymphoma (nhl) 05/26/2022
Adicet bio to present at upcoming investor conferences 05/18/2022
Adicet bio announces oral presentation of updated adi-001 phase 1 data at the 2022 american society of clinical oncology (asco) annual meeting 04/27/2022
Adicet bio receives fda fast track designation for lead candidate adi-001 04/19/2022
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 04/01/2022
Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4) 03/04/2022
Adicet bio to participate in guggenheim 2022 oncology conference 02/02/2022
Adicet bio, inc. announces closing of $100 million public follow-on offering and exercise in full of the underwriters' option to purchase additional shares 12/10/2021
Adicet bio, inc. announces pricing of public offering of common stock 12/08/2021
Adicet bio, inc. announces proposed follow-on offering of common stock 12/07/2021
Adicet bio announces positive interim clinical data from first-ever allogeneic, off-the-shelf, gamma delta car t investigational cell therapy 12/06/2021
Adicet bio to host webcast presentation of adi-001 interim clinical data in b cell non-hodgkin's lymphoma 11/29/2021
Adicet announces appointment of dr. michael g. kauffman to the board of directors 11/18/2021
Adicet presents preclinical data for adi-002, a gpc3-targeted development candidate for solid tumors, at the sitc annual meeting 11/12/2021
Adicet bio to participate in stifel 2021 virtual healthcare conference 11/08/2021
Adicet announces trials in progress poster presentation for adi-001 at 2021 ash annual meeting 11/04/2021
Cdr-life announces expansion of scientific advisory board 10/26/2021
Adicet announces promotion of blake aftab, ph.d. to chief scientific officer 10/12/2021
Adicet to present preclinical data from allogeneic gamma delta t cell platform at sitc 36th annual meeting 10/04/2021
Twist bioscience collaborates with adicet bio to accelerate discovery of gamma delta t cell cancer therapeutics 09/13/2021
Adicet bio to participate in upcoming investor conferences 09/02/2021
Adicet bio to participate in upcoming investor conferences 08/02/2021
Adicet bio announces formation of scientific advisory board 07/15/2021
Adicet bio added to the russell 2000® index 06/28/2021
Adicet bio to participate in upcoming investor conferences 05/18/2021
Adicet reports first quarter 2021 financial results and provides business updates 05/17/2021
Adicet bio appoints dr. blake aftab as vice president of research 04/13/2021
Adicet reports fourth quarter and full year 2020 financial results and provides business update 03/11/2021
Adicet bio announces initiation of its first-in-human phase 1 trial of adi-001 for the treatment of b cell non-hodgkin's lymphoma 03/10/2021
Adicet bio appoints dr. andrew sinclair to its board of directors 03/04/2021
Adicet bio, inc. announces closing of $152 million public offering and concurrent private placement and exercise in full of the underwriters' option to purchase additional shares 02/16/2021
Adicet bio to participate in upcoming investor conferences 02/11/2021
Adicet bio, inc. announces pricing of $135 million public offering of common stock and concurrent private placement 02/10/2021
Adicet bio, inc. announces proposed public offering of common stock and concurrent private placement 02/09/2021
Adicet bio to participate in fireside chat at jmp securities hematology summit 12/08/2020
Adicet announces appointment of dr. bastiano sanna to its board of directors 12/01/2020
Adicet bio to participate in upcoming investor conferences 11/06/2020
Adicet reports third quarter 2020 financial results and provides business update 11/05/2020

More Headlines

News
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York. Details of the event are as follows: Date: Monday, September 8, 2025 Time: 4:. 09/02/2025
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 29, 2025. Two individuals were hired by Adicet in August 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 84,000 shares of Adicet's common stock with an exercise price of $0.72 per. 08/29/2025
Adicet Bio (ACET) Upgraded to Buy: Here's Why Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 08/12/2025
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 45th Annual Canaccord Genuity Growth Conference being held from August 12-14, 2025 in Boston. Details of the event are as follows: Date: Tuesday, August 12, 2025. 08/05/2025
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first systemic sclerosis (SSc) patient has been dosed in the second cohort of the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. “We are pleased with the continued momentum of our Phase 1 trial of ADI-001 in autoimmune diseases as w. 07/24/2025
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York. Details of the event are as follows: Date: Wednesday, June 4, 2025 Time: 4:20. 05/21/2025
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 05/09/2025
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025. “We are approaching an exciting inflection point for our pipeline, with significant data milestones on the horizon,” said Chen Schor, President and Chief Executive Officer. 05/06/2025
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025. Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 206,800 shares of Adicet's common stock with an exercise price of $0.66 per. 04/30/2025
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, in New Orleans, LA. Details of the oral presentation are as follows: Title: ADI-270, an Armo. 04/28/2025
Adicet Bio Appoints Michael Grissinger to the Board of Directors REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. “We are honored to welcome Michael t. 04/17/2025
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on March 31, 2025. Two individuals were hired by Adicet in March 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 38,600 shares of Adicet's common stock with an exercise price of $0.76 per sh. 03/31/2025
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025. Details of the event are as follows: Panel: “CAR T Approaches in the Autoimmune Space. 03/31/2025
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2024. “In 2025 we plan to continue advancing our gamma delta 1 CAR T cell therapy programs, achieving key milestones and reporting preliminary data in autoimmune and. 03/06/2025
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A. Details of the poster presentation are as follows: Abstract Ti. 03/03/2025
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement. Fast Track Designation is a process designed. 02/05/2025
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on January 31, 2025. Two individuals were hired by Adicet in January 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 28,600 shares of Adicet's common stock with an exercise price of $0.89 pe. 01/31/2025
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference being held from February 5-6, 2025 in New York. Details of the event are as follows: Date: Wednesday, February. 01/29/2025
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2025. “2024 was a momentous year for Adicet as we amplified our efforts in autoimmune diseases and solid tumors. We dosed our first patients in our clinical trials evaluating our gamma delta 1 chimeric a. 01/08/2025
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on December 31, 2024. One individual was hired by Adicet in December 2024 and granted new hire non-qualified stock options to purchase 9,000 shares of Adicet's common stock with an exercise price of $0.96 per share, the closing p. 12/31/2024
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced ccRCC. “Dosing the first patient in our Phase 1 trial of ADI-270 in metastatic/advanced ccRCC is a significant milestone for Adicet as w. 12/19/2024
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet's robust autoimmune and oncology pipeline. “We are incredibly pleased to welcome Jul. 12/18/2024
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 29, 2024. One individual was hired by Adicet in November 2024 and granted new hire non-qualified stock options to purchase 6,000 shares of Adicet's common stock with an exercise price of $1.13 per share, the closing p. 11/29/2024
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). “Solid tumors represent one of the highest unmet medical needs in oncology and have yet to benefit from th. 11/18/2024
Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024 REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD19+ B cell depletion in secondary lymphoid tissue will be featured in an oral session at ACR Convergen. 11/16/2024
Adicet Bio to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in three upcoming investor conferences in November. Details of the events are as follows: Truist Securities BioPharma Symposium, November 7, 2024, New York, NY Members of management will be available for 1x1 meetings on. 11/01/2024
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2024. Three individuals were hired by Adicet in October 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 59,800 shares of Adicet's common stock with an exercise price of $1.28. 10/31/2024
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on September 30, 2024. Four individuals were hired by Adicet in September 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 33,600 shares of Adicet's common stock with an exercise price of $1. 09/30/2024
Adicet Bio to Present at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference, taking place October 16 – 17, 2024, in Philadelphia, PA. Details of the oral presentation are. 09/30/2024
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. “The favorable safety profile, cellular kinetics and B cell depletion in peripheral blood and secondary lymphoid tissue demonstrated with ADI-001 clinical exper. 09/30/2024
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ADI-001 as a best-in-class allogeneic cell therapy for autoimmune diseases. Notably, ADI-001 demonstrated robust tissue trafficking resulting in high levels. 09/19/2024
UL Solutions Warns of Potentially Hazardous Communications Cable NORTHBROOK, Ill.--(BUSINESS WIRE)--The following is a notification from UL Solutions that the communications cable that bears the serial numbers identified below may pose a potential fire hazard. The communications cable does not comply with the appropriate Safety Standards. Name of Product: CAT 5E 350MHZ CMR MODEL NUMBER W-CAT5E/CCU/1000/W UNSHIELDED TWISTED PAIR 24 AWG/4PAIR/1000FT Remedy: UL Solutions recommends that this product be removed from service. Identification on the Cable: E468535. 08/30/2024
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 30, 2024. Three individuals were hired by Adicet in August 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 30,600 shares of Adicet's common stock with an exercise price of $1.46 pe. 08/30/2024
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024. 07/09/2024
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering. 07/02/2024
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to evaluate ADI-270, an armored allogeneic “off-the-shelf” gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70. 06/24/2024
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally. 06/10/2024
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis. “The FDA's decision to grant ADI-001 Fast Track Designation for lupus nephritis. 06/05/2024
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on May 31, 2024. Two individuals were hired by Adicet in May 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 44,800 shares of Adicet's common stock with an exercise price of $1.45 per share,. 05/31/2024
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 5-6, 2024 in New York. Details of the event are as follows: Date: Wednesday, June 5, 2024 Time: 1:00 p.m. ET. 05/29/2024
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2024. “We are poised for a transformational year in 2024 as we advance our gamma delta T cell platform in autoimmune diseases and prepare to initiate a Phase 1 study evaluating o. 05/14/2024
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024. Details of the poster presentation are as follows: Title: ADI-270: An Armored Allogeneic Anti-CD70. 05/14/2024
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Citizens JMP Life Sciences Conference being held from May 13-14, 2024 in New York. Details of the event are as follows: Date: Tuesday, May 14, 2024 Time: 1:. 05/07/2024
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on April 30, 2024. One individual was hired by Adicet in April 2024 and granted new hire non-qualified stock options to purchase 7,800 shares of Adicet's common stock with an exercise price of $1.49 per share, the closing price o. 04/30/2024
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that an abstract featuring new preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR (chimeric antigen receptor) T cell therapy candidate targeting CD70 positive cancers, has been selected for an oral presentation at the. 04/22/2024
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024. Details of the event are as follows: Panel: “Off-the-Shelf CART – Let's Talk Lupus an. 04/08/2024
Why Adicet Bio (ACET) Stock Might be a Great Pick Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. 04/04/2024
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year. 04/01/2024
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was hired by Adicet in March 2024 and granted new hire non-qualified stock options to purchase 99,400 shares of Adicet's common stock with an exercise price of $2.35 per share, the closing price. 03/28/2024
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return. 03/28/2024
Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. 03/22/2024
ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023 Adicet Bio (NASDAQ: ACET ) just reported results for the fourth quarter of 2023. Adicet Bio reported earnings per share of -69 cents. 03/19/2024
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023. “We are excited to explore the potential of our gamma delta T cell platform in autoimmune diseases following the FDA's IND clearance of ADI-001 in lupus nephri. 03/19/2024
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year. 03/15/2024
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March 26, 2024. Details of the event are as follows: Date: Tuesday, March 26, 2024 Time: 10. 03/11/2024
3 High-Risk Stocks That Could Pay Off in the Millions High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market's appetite for risk continues to grow. 03/05/2024
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on February 29, 2024. One individual was hired by Adicet in February 2024 and granted new hire non-qualified stock options to purchase 7,000 shares of Adicet's common stock with an exercise price of $2.35 per share, the closing p. 02/29/2024
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year. 02/28/2024
7 Top-Tier Penny Stocks for a Smart Bet Penny stocks are heating up as the S&P 500 hits new highs, signaling opportunity. With the S&P 500 posting new highs multiple times in the past few months and prospects of lower interest rates, the stage is set for potentially lucrative penny stock investments. 02/27/2024
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum. 02/25/2024
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year. 02/12/2024
Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year. 01/25/2024
Adicet (ACET) Stock Rallies 130% in a Month: Here's Why Adicet (ACET) skyrockets 130% on a corporate update provided by the company discussing strategic priorities for 2024. 01/15/2024
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? Here is how Adicet Bio, Inc. (ACET) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year. 01/09/2024
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.56 per share a year ago. 08/09/2023
Adicet Bio, Inc. (ACET) Reports Q1 Loss, Misses Revenue Estimates Adicet Bio, Inc. (ACET) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to earnings of $0.10 per share a year ago. 05/09/2023
7 Biotech Stocks That Could Be the Next Big Thing While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that could be the next big thing. These lesser-known enterprises may not command worldwide attention at the moment. 03/15/2023
Adicet Bio: Searching For Upside In Cell Therapeutics Biotechs developing CAR-T cell therapies have seen their valuations plummet in 2022 - making them an intriguing speculative buy opportunity in 2023. This is a complex field characterized by study failures, issues with durability, but the six CAR-T therapies approved to date will likely all achieve blockbuster (>$1bn per annum) sales. 02/07/2023
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? Here is how Adicet Bio, Inc. (ACET) and AlloVir, Inc. (ALVR) have performed compared to their sector so far this year. 01/25/2023
Down -53.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Adicet Bio, Inc. (ACET) Adicet Bio, Inc. (ACET) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. 12/30/2022
5 Stocks to Pop Surprise Returns From Secret Santa Adicet Bio (ACET), Enfusion (ENFN), Dillard's (DDS), First BanCorp. (FBP) and Hillenbrand (HI) could bring gifts of surprise returns from Secret Santa. 12/22/2022
Adicet Bio, Inc. (ACET) Loses 47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Adicet Bio, Inc. (ACET) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. 12/14/2022
Why The Adicet Bio (ACET) Stock Plummeted Over 35% The stock price of Adicet Bio (ACET) plummeted over 35% intraday today. This is why. 12/12/2022
Adicet Bio shares fall as it shares clinical data about its CAR-T treatment candidate Adicet Bio's Inc. ACET, -13.13% stock tumbled about 38% in premarket trading on Monday after the company shared data from a Phase 1 clinical trial evaluating the company's investigational CAR-T therapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. It's "too early for a 'true' [overall response rate], [complete response], and 6-month CR rate, but profile continues to be promising," Wedbush analysts told investors on Monday morning. 12/12/2022
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year? Here is how Adicet Bio, Inc. (ACET) and Merck (MRK) have performed compared to their sector so far this year. 12/07/2022
What Makes Adicet Bio, Inc. (ACET) a Good Fit for 'Trend Investing' Adicet Bio, Inc. (ACET) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. 12/07/2022
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a webcast presentation on Sunday, December 11, 2022 at 9:00 a.m. EST to discuss the most recent data-cut from its ongoing Phase 1 study evaluating the safety and tolerability of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL. 12/02/2022
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit REDWOOD CITY, Calif. & BOSTON--( BUSINESS WIRE )--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the virtual JMP Securities Hematology and Oncology Summit being held from December 6-7, 2022. 11/30/2022
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? Here is how Adicet Bio, Inc. (ACET) and RxSight, Inc. (RXST) have performed compared to their sector so far this year. 11/11/2022
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Misses Revenue Estimates Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 5.36% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? 11/08/2022
Adicet Bio to Present at Upcoming Investor Conferences REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in September. Details of the events are as follows: H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022, New York, New York An on-d 09/07/2022
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Misses Revenue Estimates Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -24.44% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? 08/10/2022
7 Cheap Biotech Stocks to Buy Now Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate. 08/03/2022
Adicet Bio to Present at Upcoming Investor Conferences REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in August. Details of the events are as follows: BTIG Biotech Conference, August 8-9, 2022 Chen Schor, President & CEO, will participate in a fireside ch 08/01/2022
Adicet Bio: A First Take Today, we take a look at Adicet Bio for the first time. The company is pioneering what it hopes will be among the next wave of CAR-T therapies and is advancing its lead candidate. 07/22/2022
Adicet Bio, Inc. (ACET) Is a Great Choice for "Trend" Investors, Here's Why Adicet Bio, Inc. (ACET) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. 07/18/2022
Has Adicet Bio (ACET) Outpaced Other Medical Stocks This Year? Here is how Adicet Bio, Inc. (ACET) and Catalyst Biosciences, Inc. (CBIO) have performed compared to their sector so far this year. 07/14/2022
Adicet Bio to Present at Upcoming Investor Conferences REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in June. Details of the events are as follows: Truist Securities Cell Therapy Symposium, Symposia-cel, June 28, 2022 Chen Schor, President & CEO, will part 06/21/2022
Adicet Bio to Present at Upcoming Investor Conferences MENLO PARK, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in May and June. Details of the events are as follows: H.C. Wainwright Global Investment Conference, May 23-26, 2022 An on-demand presentation will be available 05/18/2022
Adicet Bio, Inc. (ACET) Surges 6.8%: Is This an Indication of Further Gains? Adicet Bio, Inc. (ACET) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. 04/28/2022
Adicet Bio, Inc. (ACET) Reports Q4 Loss, Tops Revenue Estimates Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -6.82% and 17.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? 03/15/2022
Is a Surprise Coming for Adicet Bio (ACET) This Earnings Season? Adicet Bio (ACET) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. 03/07/2022
Adicet Bio, Inc. (ACET) Expected to Beat Earnings Estimates: Should You Buy? Adicet Bio, Inc. (ACET) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 03/03/2022
Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate The company's platform is based on gamma delta 1 T cells, which have been major investor attention recently. The next data update from the above ADI-001 FIH study is expected in mid this year (likely at the EHA conference from June 9-12 (the next key catalyst). 02/08/2022
3 Biotech Stocks That Could Make You Richer in February (and Beyond) These companies' share prices could rise in the short term, but their long-term opportunities are even better. 02/05/2022
3 Biotech Stocks That Could Double in 2022 They're risky. But with the high risk comes the potential for high rewards. 01/03/2022
Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma Candidate Adicet Bio Inc (NASDAQ: ACET) priced an underwritten public offering of 6.25 million shares at $14.00 per share, raising gross proceeds of $87.5 million. The offer price represents a discount of almost 3% from the last close price of $14.49 on Tuesday. 12/08/2021
Adicet Bio Stock (ACET): Why The Price Surged Today The stock price of Adicet Bio Inc (NASDAQ: ACET) increased by over 40% pre-market today. This is why it happened. 12/06/2021
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data in B Cell Non-Hodgkin's Lymphoma ADI-001 is the first ever allogeneic, off-the-shelf, gamma delta CAR T cell therapy to report clinical data 11/29/2021
Adicet Bio, Inc. (ACET) Reports Q3 Loss, Lags Revenue Estimates Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -15.79% and -26.26%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? 11/10/2021
Adicet Announces Promotion of Blake Aftab, Ph.D. to Chief Scientific Officer MENLO PARK, Calif. and BOSTON, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced Blake Aftab, Ph.D., has been promoted to the position of Senior Vice President and Chief Scientific Officer. In this role, Dr. Aftab will be responsible for the continued expansion of Adicet's pipeline of therapeutic candidates in solid and hematologic tumors. 10/12/2021
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting MENLO PARK, Calif. and BOSTON, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the Company will present data in the form of a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting to be held November 10-14, 2021. 10/04/2021
Adicet Bio to Participate in Upcoming Investor Conferences MENLO PARK, Calif. and BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two upcoming virtual investor conferences in September. 09/02/2021
Adicet Bio, Inc. (ACET) Reports Q2 Loss, Tops Revenue Estimates Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of 33.33% and 6.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock? 08/12/2021
Adicet Bio to Participate in Upcoming Investor Conferences MENLO PARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in three upcoming virtual investor conferences in August. 08/02/2021
Adicet Bio Added to the Russell 2000® Index MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the Company has been added to the Russell 2000® Index, effective June 28, 2021, as part of the 2021 Russell indexes annual reconstitution. 06/28/2021
Moving Average Crossover Alert: Adicet Bio (ACET) Adicet Bio (ACET) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. 06/01/2021
Adicet Bio to Participate in Upcoming Investor Conferences MENLO PARK, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two upcoming virtual investor conferences in May and June. 05/18/2021
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates MENLO PARK, Calif. and BOSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the first quarter ended March 31, 2021. 05/17/2021
Week 17 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge Two new breakout stocks for Week 17 with better than 10% short-term upside potential. For only the 2nd time this year, none of the 4 picks broke above 10% this week in the first negative week for the S&P 500 in 5 weeks. 04/25/2021
Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Blake Aftab, Ph.D., as Vice President of Research. Dr. Aftab will lead Adicet's research group and will further develop existing and new opportunities for the Company's gamma delta T cell platform. 04/13/2021
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update MENLO PARK, Calif. and BOSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020. 03/11/2021
Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma MENLO PARK, Calif. and BOSTON, Mass. 03/10/2021
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Andrew Sinclair, Ph.D., to its board of directors. Dr. Sinclair will replace Erez Chimovits, who will step down from the Board of Directors. 03/04/2021
Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the closing of an underwritten public offering of 10,575,513 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,344,743 shares of common stock at a public offering price of $13.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses were approximately $137.5 million. All of the shares in the offering are to be sold by Adicet. 02/16/2021
Adicet Bio to Participate in Upcoming Investor Conferences MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the company management will participate in three upcoming virtual investor conferences. 02/11/2021
Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement MENLO PARK, Calif. and BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a public offering price of $13.00 per share. Adicet also granted the underwriters a 30-day option to purchase up to an additional 1,344,743 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $120.0 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Adicet. The offering is expected to close on or about February 12, 2021, subject to customary closing conditions. 02/10/2021
Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management Adicet Bio is a biotechnology company concentrated on developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a pre-clinical pipeline of 4 therapeutics covering various indications with the lead two candidates (ADI-001 and -002) being molecularly very similar offering lower clinical diversification. 12/28/2020
Adicet Bio (ACET) Surges: Stock Moves 5.9% Higher Adicet Bio (ACET) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes. 12/18/2020
Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate in a fireside chat at The JMP Securities Hematology Summit on Tuesday, December 15, 2020 at 2:00 PM ET. 12/08/2020
Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Bastiano Sanna, Ph.D., to its Board of Directors. Dr. Sanna brings significant expertise in advancing research, development and manufacturing of cell therapies. He currently serves as Executive Vice President and Chief of Cell and Genetic Therapies at Vertex Pharmaceuticals Incorporated. 12/01/2020
Adicet Bio to Participate in Upcoming Investor Conferences MENLO PARK, Calif. and BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in upcoming virtual investor conferences and events in November and December. 11/06/2020
Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the third quarter ended September 30, 2020. 11/05/2020
Nasdaq to delist two suspended medical companies 05/31/2019
New Mountain Capital acquires ACETO's chemicals business 04/16/2019
6 Poorly Performing Stocks 03/19/2019
Aceto Corp shares are trading higher on continued strength after the company on Thursday entered into a stalking horse agreement to sell Rising Pharmaceuticals for $15 million. 03/11/2019
ACETO Enters into Stalking Horse Agreement to Sell Rising Pharmaceuticals 03/08/2019
Aceto shares are trading higher, now up over 100% in what looks to be a rebound from last week's weakness which was triggered by the company's announcement of Chapter 11 bankruptcy. 02/27/2019
Aceto shares are trading lower on continued weakness after the company filed for Ch 11 bankruptcy relief and announced the proposed sale of its chemicals business for $338 million. 02/21/2019
75 Biggest Movers From Yesterday 02/21/2019
Mid-Afternoon Market Update: Crude Oil Up 1.5%; Kandi Technologies Shares Spike Higher 02/20/2019
54 Stocks Moving In Wednesday's Mid-Day Session 02/20/2019
ACETO shares are trading lower after the company filed for Ch 11 bankruptcy relief and announced the proposed sale of its chemicals business for $338 million. 02/20/2019
ACETO Announces Proposed Sale of its Chemicals Business Assets to New Mountain Capital for $338M 02/20/2019
Pioneer Energy Services and Devon Energy among Energy/Materials gainers; Aceto and Synalloy among losers 02/20/2019
Precision Drilling and Materion among Energy/Materials gainers; Phunware and New Gold among losers 02/14/2019
TEVA, BABY and QLYS among premarket losers 02/13/2019
Tronox and Torchlight Energy Resources among Energy/Materials gainers; Bristow Group and Callon Petroleum among losers 02/12/2019
Aceto and Forum Energy Technologies among Energy/Materials gainers; MagneGas Applied Technology Solutions and Superior Energy Services among losers 02/08/2019
ION Geophysical and Aceto among Energy/Materials gainers; Valvoline and Adient among losers 02/07/2019
Amyris and Aceto among Energy/Materials gainers; MagneGas Applied Technology Solutions and Cabot among losers 02/05/2019
Versum Materials and IAMGOLD among Energy/Materials gainers; Vale and W&T Offshore among losers 01/28/2019
Universal Stainless & Alloy Products leads Energy/Materials gainers; Valhi and Aceto among losers No summary available. 01/24/2019
Universal Stainless & Alloy Products leads Energy/Materials gainers; Valhi and Aceto among losers 01/24/2019
Ossen Innovation and Arcadia Biosciences among Energy/Materials gainers; Legacy Reserves and PEDEVCO among losers 01/16/2019
Valhi and Aceto among Energy/Materials gainers; Legacy Reserves and PEDEVCO among losers Gainers: Valhi (VHI) +23%. Aceto (ACET) +19%. Quintana Energy Services (QES) +8%. Superior Drilling Products (SDPI) +8%. Ossen Innovation (OSN) +6%. Losers 01/15/2019
Valhi and Aceto among Energy/Materials gainers; Legacy Reserves and PEDEVCO among losers 01/15/2019
Teva outlook on stable prices buoys generics 01/07/2019
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018 12/20/2018
Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018 12/19/2018
Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018 12/17/2018
Stocks Which Set New 52-Week Low Yesterday, Thurs., Dec. 13, 2018 12/14/2018
Generics under pressure on expanded price-fixing investigation 12/10/2018
85 Biggest Movers From Friday 11/12/2018
Aceto Corp. (ACET) CEO Bill Kennally on Q1 2019 Results - Earnings Call Transcript 11/10/2018
68 Stocks Moving In Friday's Mid-Day Session 11/09/2018
Aceto Q1 EPS $(0.59) Misses $(0.05) Estimate, Sales $164.405M Miss $166.2M Estimate 11/08/2018
Stocks Which Set New 52-Week Low Friday, October 26th 10/29/2018
Stocks Which Set New 52-Week Low Yesterday, October 23rd 10/24/2018
Stocks Which Set New 52-Week Low Yesterday, October 22nd 10/23/2018
ACETO Corporation Schedules First Quarter & Fiscal —…–9 Financial Results News ... 10/22/2018
Aceto files for $200M mixed shelf offering 10/20/2018
FDA issues new guidance for developers of complex generics 10/09/2018
Generics in the green following proposed favorable guidance from FDA 10/02/2018
The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results 09/28/2018
41 Biggest Movers From Yesterday 09/27/2018
30 Stocks Moving In Wednesday's Mid-Day Session 09/26/2018
UPDATE: Garrett Motion To Replace Aceto In S&P SmallCap 600 09/25/2018
Stocks That Will Be Trading Ex Dividend Fri., Sep. 21, 2018 09/20/2018
Earnings Scheduled For September 12, 2018 09/12/2018
ACETO Corporation Schedules Fourth Quarter & Fiscal —…–8 Financial Results News ... 08/30/2018
Energy/Materials - Top Gainers / Losers as of 2:00 PM (08/29/2018) 08/29/2018
Mylan's trimmed guidance may pressure generic drug makers 08/08/2018
Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (07/17/2018) 07/17/2018
ACETO Shares Up 11.6% After Co.'s Subsidiary Acetris Health Received Favorable Ruling Regarding Government Contracts 07/16/2018
Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (07/10/2018) 07/10/2018
45 Biggest Movers From Tuesday 07/05/2018
SHAREHOLDER ALERT – ACET MFGP PPG: The Law Offices of Vincent Wong Reminds Investors of ... 06/22/2018
The Law Offices of Howard G. Smith Reminds Investors of June —5th Deadline in the Class ... 06/21/2018
Hagens Berman Reminds Investors in Aceto Corporation (ACET) of the June —5, —…–8 ... 06/18/2018
ACETO SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of ... 06/16/2018
UPDATE -- The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of ... 06/15/2018
The Klein Law Firm Reminds Investors of Class Actions Commenced on Behalf of Shareholders of ... 06/14/2018
Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (06/12/2018) 06/12/2018
45 Biggest Movers From Yesterday 06/06/2018
Dividends By The Numbers For May 2018 06/05/2018
ACETO Names Alan Levin Non-Exec Chair 06/01/2018
Energy/Materials - Top Gainers / Losers as of 2:00 PM (05/31/2018) 05/31/2018
The Klein Law Firm Reminds Investors of a Class Action on Behalf of Aceto Corporation ... 05/25/2018
ACET EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action ... 05/23/2018
Hagens Berman Alerts Investors in Aceto Corporation (ACET) to the June —5, —…–8 ... 05/10/2018
Aceto Corporation 2018 Q3 - Results - Earnings Call Slides 05/07/2018
ACETO SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF ... 05/05/2018
Aceto's (ACET) CEO Bill Kennally on Q3 2018 Results - Earnings Call Transcript 05/04/2018
Aceto Q3 EPS $0.01, Sales $185.998M Beat $180.12M Estimate 05/03/2018
Pomerantz Law Firm Announces the Filing of a Class Action against Aceto Corporation and Certain ... 04/25/2018
35 Biggest Movers From Yesterday 04/24/2018
28 Stocks Moving In Monday's Mid-Day Session 04/23/2018
32 Biggest Movers From Yesterday 04/20/2018
Mid-Afternoon Market Update: Dow Slides 160 Points; Helios and Matheson Analytics Shares Plunge 04/19/2018
ACETO Shares Down 28.9% After Hours Following Announcement Of Financial Challenges; Co. Has Suspended Further Guidance And Is Evaluating Strategic Alternatives, Expects Reduction In Dividend Moving Forward 04/18/2018
Energy/Materials - Top Gainers / Losers as of 2:00 pm (04/09/2018) 04/09/2018
New Strong Sell Stocks for April 6th 04/06/2018
New Strong Sell Stocks for April 4th 04/04/2018
New Strong Sell Stocks for March 16th 03/16/2018
ACETO Reports Will Appeal US Gov't. Ruling Related To Certain Lucid Pharma Contracts 02/27/2018
The Best And Worst Performing Stocks On Earnings This Season 02/21/2018
ACETO Names Edward J. Borkowski CFO 02/16/2018
Energy/Materials - Top Gainers / Losers as of 2:00 pm 02/13/2018
ACETO Reports Rising Pharma Subsidiary Launched Atenolol Tablets 25mg, 50mg, 100mg 02/07/2018
40 Biggest Movers From Friday 02/05/2018
Mid-Afternoon Market Update: Crude Oil Down 1.5%; Natural Grocers Shares Drop On Earnings Miss 02/02/2018
Aceto Sees FY!8 Adj. EPS $1-$1.05 vs $1.08 Est., Sales Growth 10-15% 02/01/2018
Notable earnings after Thursday's close 01/31/2018
ACETO Reports Subsidiary Rising Pharma Launched Efavirenz Capsules, 50, 200mg 01/02/2018
Aceto Corporation declares $0.065 dividend 12/07/2017
Energy/Materials - Top Gainers / Losers as of 2:00 pm 12/04/2017
ACETO Sees FY18 Adj. EPS $1.05-$1.15 vs $1.28 Est., Sales Growth 15-20% 11/02/2017
ACETO Reports Rising Pharma Subsidiary Launched Sertraline Oral Solution, 20mg/ml 10/24/2017
ACETO Corporation Schedules First Quarter Fiscal —…–8 Financial Results News Release and ... 10/20/2017
ACETO Names William C. Kennally, III President, CEO 09/27/2017
Weakness Seen in Aceto Corporation (ACET) Estimates: Should You Stay Away? 08/31/2017
12 Biggest Mid-Day Losers For Friday 08/25/2017
Earnings Scheduled For August 24, 2017 08/24/2017
Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media 08/22/2017
5 Stocks to Bet on New Analyst Coverage 08/21/2017
ACETO Corporation Schedules Fourth Quarter & Fiscal —…–7 Financial Results News ... 08/11/2017
15 Biggest Mid-Day Gainers For Monday 07/31/2017
ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets At Multiple Dose Ranges 06/20/2017
ACETO Subsidiary, Rising Pharmaceuticals, Launches Atomoxetine Capsules, –…, –8, —5, ... 05/31/2017
AlphaOne Investment Services, LLC Buys HP Inc, Lumentum Holdings Inc, FireEye Inc, Sells CBS ... 05/09/2017
20 Biggest Mid-Day Losers For Friday 05/05/2017
ACETO Q3 EPS $0.39 vs $0.44 Est, Sales $190.1M vs $195.1M Est 05/04/2017
Buy Aceto Before Earnings - ACET 05/02/2017
ACETO Reports Subsidiary, Rising Pharma, Has Launched Zileuton ER Tablets, 600 mg 03/31/2017
ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, –5… & 5…… mg 03/28/2017
Top Ranked Value Stocks to Buy for March 6th 03/06/2017
Top Ranked Value Stocks to Buy for February 28th 02/28/2017
A New Buffett-Inspired Screening Model 02/27/2017
9 Cheap High-Yield Stocks 02/23/2017

Unlock

ACET Ratings Summary

ACET Quant Ranking